Neurosteroid Derivative Structure for Stable Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current neurosteroid drugs targeting GABA-A receptors, such as allopregnanolone and ganaxolone, suffer from low water solubility and metabolic instability, leading to insufficient bioavailability and limitations in clinical application.
Innovation Solution
Development of a compound with a specific structure represented by formula (I) and its derivatives, including stereoisomers, tautomers, isotope-enriched analogs, and pharmaceutically acceptable salts, which exhibit improved in vivo metabolic stability and bioavailability, allowing for non-intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If neurosteroid drugs such as allopregnanolone and ganaxolone are used to target GABA-A receptors, then therapeutic effects on central nervous system diseases are achieved, but water solubility is low and metabolic instability occurs, leading to insufficient bioavailability
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of neurosteroid compounds. Specifically, it introduces various substituents (R1 and R2 groups) at different positions of the steroid core structure, changes saturation levels of rings, and modifies functional groups to optimize both metabolic stability and bioavailability while maintaining GABA-A receptor modulatory activity
Solution Approach 2:
The patent creates composite molecular structures by combining the neurosteroid core framework with additional functional moieties. The compounds represent composite structures integrating the steroid nucleus with modified side chains and substituent groups that collectively provide enhanced metabolic stability, improved solubility characteristics, and maintained pharmacological activity
2Reliability
If structural modifications are made to improve water solubility, then drug absorption and bioavailability are enhanced, but metabolic stability may be compromised
Solution Approach 1:
The patent applies local quality by making targeted modifications at specific positions of the steroid molecule rather than uniform changes throughout. Different substituents are placed at specific rings and positions (R1 at C17, R2 at C20, etc.) to locally enhance solubility or stability without compromising the overall molecular integrity and pharmacological function
3Stability of the object's composition
If structural modifications are made to reduce metabolic rate, then oral administration becomes feasible, but water solubility and absorption may be affected
Solution Approach 1:
The patent systematically varies chemical parameters including substituent types, ring saturation, and functional group configurations to find the optimal balance between metabolic stability and oral bioavailability. The structure-activity relationship studies guide the selection of parameters that simultaneously achieve reduced metabolic rate and maintained solubility for oral administration
Data Source
AI summary
A neurosteroid derivative having a structure as represented by formula (IV), or a deuteride, and a pharmaceutically acceptable salt thereof, and use thereof are provided. In the formula (IV), R1 is selected from the group consisting of hydrogen and C1-C12 alkyl; and R2 is selected from R—(C═O)—, wherein R is selected from the group consisting of hydrogen and C1-C12 alkyl.